Postoperative Outcomes and Reinterventions Following Fenestrated/Branched Endovascular Aortic Repair in Post-Dissection and Complex Degenerative Abdominal and Thoraco-Abdominal Aortic Aneurysms

Bright Benfor 1,*, Julia Högl 1, Ryan Gouveia e Melo 1, Jan Stana 1, Carlota Fernandez Prendes 1, Maximilian Pichlmaier 2, Barbara Rantner 1 and Nikolaos Tsilimparis 1

1 Department of Vascular Surgery, Ludwig Maximilian University Hospital, 81377 Munich, Germany
2 Department of Heart Surgery, Ludwig Maximilian University Hospital, 81377 Munich, Germany
* Correspondence: bright.benfor@usmba.ac.ma; Tel.: +49-89-4400-76515

Abstract: Background: The outcome of FBEVAR in post-dissection thoracoabdominal aortic aneurysms has not been well established in the literature. The aim of this study was to compare midterm outcomes following FBEVAR in post-dissection aneurysms to degenerative aneurysms. (2) Methods: This was a retrospective review of all patients undergoing FBEVAR in a single center between 2017 and 2020. The baseline characteristics, intraoperative details, and postoperative outcomes of patients with post-dissection aneurysms were compared to those with degenerative outcomes. The primary end point was unplanned reinterventions. Cox regression analysis was performed to identify the determinants of worse outcomes. Results: A total of 137 subjects with a mean age of 70 ± 10 years were included in the study, out of which 30 presented post-dissection aneurysms (22%). Custom-made devices were employed in 119 patients, off-the-shelf devices in 13 and physician-modified endografts in 5, with incorporation in 505 target vessels. The technical success rate was comparable in both groups (97% vs. 98%, p = 0.21). However, the one-year freedom from unplanned reintervention was lower in the post-dissection group (67% vs. 89%, p = 0.011). Conclusion: FBEVAR in post-dissection aneurysms is associated with a favorable technical success rate, but reintervention rates remain high. Long procedural duration and the use of adjunctive techniques are associated with increased risk of reinterventions.

Keywords: fenestrated endovascular aortic repair; branched endovascular aortic repair; thoracoabdominal aortic aneurysms; complex aortic aneurysms; FEVAR; BEVAR

1. Introduction

Aneurysmal degeneration is a frequent chronic complication of aortic dissection with an estimated 5-year incidence of 73% among patients with type B dissection on medical therapy alone versus 63% after thoracic endovascular aortic repair [1]. As such, aortic dissection is the second most common etiology of aortic aneurysms after atherosclerotic degenerative aneurysms, accounting for 15–20% of all thoracoabdominal aortic aneurysms (TAAAs) [2]. The risk of rupture and of aneurysmal-related death in TAAAs is estimated at 3.7% and 12% per year, respectively, with aneurysmal size being the major predictive factor of rupture. Thus, timely intervention to exclude large aneurysms plays a critical role in the survival of these patients. Endovascular aortic repair using fenestrated and branched endografts to incorporate aortic branch vessels offers a less invasive approach to aneurysmal exclusion and may potentially reduce the rate of perioperative morbidity and mortality [3]. Previous studies have reported promising results with fenestrated and branched endovascular aortic repair (FBEVAR) in the treatment of complex aortic aneurysms [3–5]. However, there is a scarcity of literature regarding the comparative outcomes of FBEVAR in post-dissecting aneurysms, and the influence of chronic aortic dissection on FBEVAR has not been well established. Their
outcomes may differ from those of degenerative aneurysms due to anatomic complexity and intraoperative challenges. The aim of this present study was to compare the clinical characteristics and outcomes of fenestrated/branched endovascular aortic repair in post-dissection aneurysms to degenerative aneurysms, in an “all-comers” cohort.

2. Materials and Methods

2.1. Type of Study and Setting

This was a retrospective cohort study performed in the Vascular Surgery department of a tertiary referral center in Germany to evaluate the outcomes of fenestrated and branched endovascular aortic repair in the treatment of complex abdominal and thoraco-abdominal aneurysms, with a specific focus on post-dissection aneurysms. The study was approved by the Institutional Review Board, and all patients gave an informed consent prior to surgery.

2.2. Patient Population

Consecutive patients receiving complex endovascular aortic repair with either fenestrated or branched aortic endografts for degenerative or post-dissection abdominal and thoracoabdominal aneurysms between January 2017 and January 2020 were included in this study. Patients’ preoperative, surgical and follow-up data, which had been prospectively collected in the institution’s electronic medical records platform, were retrospectively analyzed. Data collected included demographics, cardiovascular risk factors, comorbidities, clinical characteristics, radioanatomical features, operative details and postoperative outcomes.

2.3. Preoperative Management and Planning

Prior to surgery, a computerized tomographic angiography (CTA) with slice thickness not greater than 1.25 mm was obtained of the entire aorta and iliofemoral vessels in all patients for preoperative planning and sizing of endograft. Thoracoabdominal aneurysms were described according to their extent based on the Crawford classification (i.e., Crawford extents I-IV), and abdominal aneurysms were classified as paravisceral, pararenal, juxtarenal or infrarenal based on the SVS Fenestrated and Branched EVAR Reporting standards’ proposed anatomical site classification of TAAAs and AAAs [6]. Furthermore, Crawford extents I-III were termed as being extensive, whereas Crawford extent IV and AAAs were described as being non-extensive. Indication for treatment included aneurysm size $\geq 55$ mm or evidence of progressive growth $\geq 10$ mm per year or 5 mm per 6-month period. Symptomatic and ruptured aneurysms were treated irrespective of aneurysmal size. Further preoperative workup was performed to assess patients cardiac, respiratory, renal and other vital parameters before surgery. The physical status of patients was evaluated using the American Society of Anesthesiology (ASA) preoperative score. Preoperative medical management included blood pressure medication, antiplatelet therapy, anti-diabetic treatment, optimization of cardiac medication and smoking cessation. Patients were either treated using custom-made devices or an off-the-shelf thoracoabdominal multibranched endograft (T-branch®, Cook medical, Bloomington, IN, USA). Surgeon-modified fenestrated-branched endografts were also used in urgent situations when a T-branch® was not anatomically feasible. All proximal components were oversized to 10–20% of the proximal landing zone diameter as determined on preoperative imaging. Likewise, iliac limbs were oversized to 10–15% of the distal seal zone diameter. Generally, caudally-oriented directional branches were preferred to fenestrations in patients with wide visceral aorta ($\geq 30$ mm). Inner side branches as well as retrograde branches were selectively used to incorporate target vessels in some patients, depending on the anatomy and at the discretion of the surgeon.

2.4. Surgical Procedure and Follow-Up

Procedures were typically performed in a hybrid room under general anesthesia. Spinal drainage was used in patients with extensive thoraco-abdominal aneurysms to reduce the risk of spinal cord ischemia (SCI). The drain was placed before the procedure and left in place for 48 to 72 h postoperatively. Similarly, Minimally Invasive Segmental Coil
Embolization (MISACE) was performed in certain patients prior to the index procedure. Preoperative debranching of the left subclavian artery was required to extend the PLZ in certain patients with extensive TAAAs. Femoral access was achieved either by surgical cut-down in the groins or most commonly by percutaneous ultrasound-guided access with the use of suture-based preclosure devices (PROGLIDE, Abbott Vascular, Redwood City, CA, USA). When anatomically favorable, the right groin access was preferred for introduction of the main aortic components of the endograft, and fenestrations were generally cannulated from the contralateral femoral access. On the other hand, anterograde access from the arm or axillary region was generally used to cannulate caudally-oriented directional branches. However, in selected cases, transfemoral access was used to cannulate these branches. Endografts with precannulated fenestrations were employed in patients with extremely narrow or diseased contralateral iliac access. The choice of bridging stent type was at the discretion of the principal operator, with the choice of diameter and length being guided by preoperative imaging with an oversizing of 0–10%. All bridging stents were flared inside the aortic lumen to a diameter of +2 mm of the nominal diameter. Intraoperative fusion imaging guidance was routinely performed in our cohort, and postoperative CTA was required in all patients before discharge. After the procedure, patients were closely monitored in a dedicated intensive care unit (ICU) or intermediate care (IMC) for 24 to 48 h before being transferred to a normal ward. Upon discharge and in the absence of any complications, patients were followed up at 30 days with a CTA, then at 6 months with a duplex ultrasound, at 12 months with CTA and yearly thereafter with CTA.

2.5. Outcome Measures and Definition of Variables

The primary end point of our study was unplanned graft-related reintervention defined according to the SVS reporting standards on FBEVAR [6] as any unplanned secondary procedure designed to treat the underlying aortic disease, a complication of the main aortic endograft or to treat a branch vessel instability. This consisted of open conversion, interventions for endoleaks, treatment of target vessel stenosis, thrombosis and graft limb occlusions. Surgical or endovascular management of access complications and non-graft limb-related acute limb ischemia was not included in this definition. Secondary end points were mortality, cumulative rate of types I and III endoleaks, aneurysmal rupture, aneurysm sac progression or shrinkage, target vessel instability and major adverse events including access site complications, acute limb ischemia, spinal cord ischemia, cardiac dysfunction, kidney impairment, mesenteric ischemia, respiratory dysfunction necessitating mechanical ventilation or prolonged intubation, postoperative stroke and sepsis. Sac progression was defined by aneurysm growth ≥5 mm, and shrinkage was defined as a decrease in aneurysm size ≥5 mm compared to baseline diameter. Type 1b endoleaks which were present on completion of the angiogram and intentionally left for a second staged iliac side branch or distal extension were not considered adverse events, nor were the corresponding secondary procedures considered as reinterventions in this study. The primary exposure studied was the presence of chronic dissection in the aneurysmal segment being treated.

2.6. Statistical Analysis

Continuous variables were expressed either as mean ± standard deviation or as median [range] depending on their distribution, while categorical variables were expressed as percentages. Patients were divided into two groups depending on the etiology of their aneurysm (i.e., degenerative or post-dissection) and compared for differences in demographics, anatomical features, clinical presentation, intraoperative and postoperative outcomes. Categorical variables were compared using a chi-squared test or a Fisher exact test where applicable, and continuous variables were compared using a two-sample t-test when normally distributed or a Wilcoxon Rank Sum test where variables were not normally distributed. Kaplan–Meier survival curves and failure plots were used to describe and compare freedoms from reintervention, mortality and types I and III endoleaks and mortality. All statistics were two-tailed, and a p-value < 0.05 was considered significant.
Statistical analyses were performed with IBM SPSS Statistics for Windows, Version 26.0. (IBM Corp., Armonk, NY, USA).

3. Results
3.1. Demographics and Baseline Characteristics
A total of 137 patients underwent fenestrated or branched endovascular aortic repair during the study period. Out of these, 107 (78%) presented degenerative aneurysms and 30 (22%) presented post-dissection aneurysms. Their mean age was 70 ± 10 years and 31 (23%) were female. Patients with post-dissection aneurysms were significantly younger than those presenting degenerative aneurysms, with a mean age of 60 ± 11 years versus 73 ± 7 years, respectively (p-value < 0.0001), while patients with degenerative aneurysms tended to be active smokers (39.2% vs. 10.7%, p-value < 0.005) and trended towards more cardiovascular comorbidities than their post-dissection counterparts (Table 1). On the other hand, there was no significant difference between both groups in ASA physical score, cardiac ejection fraction or baseline glomerular filtration rate (GFR). Degenerative aneurysms were less extensive compared to post-dissection aneurysms (19.6% vs. 70.0%; p-value < 0.0001) and MISACE, and prior aortic repair was more frequently encountered in the post-dissection group (Table 1). In addition, significant access vessel calcification was less common in post-dissection aneurysms (13.3% vs. 38.3% p-value = 0.010).

Table 1. Demographics and baseline characteristics of patients undergoing fenestrated and branched endovascular repair for thoraco-abdominal and abdominal aneurysms.

| Variable * | All Patients (n = 137) | Degenerative Aneurysms (n = 107) | Post-Dissection Aneurysms (n = 30) | p-Value |
|------------|------------------------|----------------------------------|----------------------------------|---------|
| Age, years | 70.4 ± 9.9             | 73.3 ± 7.3                       | 59.9 ± 10.9                      | 0.000   |
| Gender, Female | 31 (22.6)             | 21 (19.6)                        | 10 (33.3)                        | 0.113   |
| BMI, kg/m² | 26.8 ± 4.9             | 26.6 ± 4.9                       | 27.4 ± 4.9                       | 0.416   |
| ASA score  | 2                     | 3 (2.2)                          | 3 (2.8)                          | 0 (0.0) |
|            | 3                     | 101 (73.7)                       | 80 (74.7)                        | 21 (70.0)|
|            | 4                     | 32 (23.4)                        | 23 (21.5)                        | 9 (30.0) |
| Ejection fraction, % | 62.7 ± 11.7          | 61.4 ± 12.6                      | 66.9 ± 6.3                       | 0.099   |
| Cardiovascular Comorbidities |  |  |  |  |
| CAD        | 35 (25.5)             | 33 (30.8)                        | 2 (6.7)                          | 0.007   |
| MI         | 9 (6.6)               | 8 (7.5)                          | 1 (3.3)                          | 0.683   |
| Arrhythmia | 35 (25.5)             | 29 (27.1)                        | 6 (20.0)                         | 0.416   |
| CHF        | 17 (12.4)             | 16 (15.0)                        | 1 (3.3)                          | 0.086   |
| Hypertension | 112 (81.7)           | 85 (79.4)                        | 27 (90.0)                        | 0.213   |
| Ischemic stroke or TIA | 17 (12.4)             | 16 (15.0)                        | 1 (3.3)                          | 0.119   |
| PAD        | 17 (12.4)             | 14 (13.1)                        | 3 (10.0)                         | 0.764   |
| Diabetes mellitus | 18 (13.1)           | 17 (15.9)                        | 1 (3.3)                          | 0.122   |
| Active smoker | 43 (31.4)             | 40 (37.4)                        | 3 (10.0)                         | 0.005   |
### Table 1. Cont.

| Variable * | All Patients (n = 137) | Degenerative Aneurysms (n = 107) | Post-Dissection Aneurysms (n = 30) | p-Value |
|------------|------------------------|----------------------------------|----------------------------------|---------|
| COPD       | 24 (17.5)              | 21 (19.6)                        | 3 (10.0)                         | 0.283   |
| GFR, ml/min| 67.9 ± 23.0            | 67.0 ± 21.2                      | 71.1 ± 28.3                      | 0.381   |
| Connective tissue disorder | 2 (1.5) | 1 (0.9) | 1 (3.3) | 0.394 |
| Antiplatelet therapy | 120 (87.6) | 94 (87.9) | 26 (86.7) | 0.999 |
| Statin use  | 92 (67.2)             | 75 (70.1)                        | 17 (56.7)                        | 0.145   |
| ACE inhibitors | 95 (69.3) | 74 (69.2) | 21 (70.0) | 0.984 |
| Betablockers| 92 (67.2)             | 68 (63.6)                        | 24 (80.0)                        | 0.101   |
| Hostile abdomen | 18 (13.2) | 16 (15.0) | 2 (6.7) | 0.299 |
| Preoperative debranching | 7 (5.1) | 1 (0.9) | 6 (20.0) | 0.000 |
| Preoperative MISACE | 54 (39.4) | 31 (29.0) | 23 (76.7) | 0.000 |
| Prior aortic surgery | 49 (35.7) | 24 (22.4) | 25 (83.3) | 0.000 |
| Endovascular | 28 (20.4) | 18 (16.8) | 10 (33.3) | 0.000 |
| Open | 10 (7.3) | 4 (3.8) | 6 (20.0) | 0.000 |
| Both | 11 (8.0) | 2 (1.9) | 9 (30.0) | 0.000 |
| Aneurysm size | 61.9 ± 15.4 | 63.2 ± 16.1 | 57.4 ± 11.9 | 0.067 |
| Status of aneurysm | | | | 0.133 |
| Asymptomatic | 117 (85.4) | 89 (83.2) | 29 (96.7) | 0.000 |
| Symptomatic non-ruptured | 14(10.2) | 13(12.1) | 1(3.3) | 0.000 |
| Ruptured | 6(4.4) | 6(5.6) | 0(0) | 0.000 |
| Extent of aneurysm | | | | 0.000 |
| Extensive TAAA (I-III) | 42 (30.7) | 21 (19.6) | 21 (70.0) | 0.000 |
| AAA/Crawford IV | 95 (69.3) | 86 (80.4) | 9 (30.0) | 0.000 |
| Significant iliac calcification | 45 (32.8) | 41 (38.3) | 4 (13.3) | 0.010 |
| Iliac tortuosity index (n = 135) | 1.3 ± 0.2 | 1.3 ± 0.2 | 1.3 ± 0.1 | 0.098 |

AAA: abdominal aortic aneurysm; ACE: angiotensin-converting enzyme; CAD: coronary heart disease; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; MI: myocardial infarction; MISACE: minimally-invasive segmental artery coil embolization; PAD: peripheral heart disease; TAAA: thoracoabdominal aortic aneurysm. * Categorical variables are presented as n, (%) and continuous variables as mean ± standard deviation or median (inter-quartile range).

### 3.2. Procedural Details

Out of the 137 procedures, 117 were elective, 14 were emergency procedures to treat ruptured aneurysms, and 6 were urgent repairs of symptomatic intact aneurysms. Urgent/emergency repair was more frequent in the degenerative aneurysm group (21.5% vs. 3.3%; p = 0.021). Custom-made devices were employed in 119 patients, off-the-shelf multibranched devices (T-branch®, Cook Medical) in 13 patients, and surgeon-modified endografts in 5 cases, with femoral access being percutaneous in 123 patients (89.8%). A total of 505 target vessels were incorporated by 333 fenestrations (65.9%), 150 directional branches (29.7%), and 22 scallops (4.4%). There was no significant difference between the two groups regarding the average number of target vessels incorporated (3.9 ± 0.3...
vs. 3.6 ± 0.8, p-value = 0.095); however, post-dissection aneurysms were more likely to have coeliac trunk incorporation (96.7% vs. 72%, p-value = 0.004). The modality of target vessel incorporation and types of bridging stents used are illustrated in Figures 1 and 2, respectively. Accessory renal arteries were incorporated in a total of seven subjects (5%). Adjunctive procedures performed included aortic bifurcation relining in 14 cases (10.2%) and iliac side branch implantation in 31 cases (22.6%). Post-dissection aneurysms presented a higher tendency for adjunct procedures (56.7% vs. 22.4%, p-value < 0.0001). In addition, the volume of contrast product used was significantly higher in post-dissection aneurysms (median of 400 mL vs. 300 mL, p-value = 0.009). However, there was no significant difference in fluoroscopy time nor in total procedure duration. Table 2 presents a comprehensive report of procedural details.

Figure 1. Bar graph of type of target vessel incorporation in fenestrated/branched endovascular aortic repair; CT: coeliac trunk; SMA: superior mesenteric artery; RRA: right renal artery; LRA: left renal artery; ARA: accessory renal artery.

Figure 2. Bridging stents used to incorporate the reno-mesenteric arteries in fenestrated and branched endovascular repair of the aorta; CT: coeliac trunk; SMA: superior mesenteric artery; RRA: right renal artery; LRA: left renal artery.
Table 2. Intraoperative details of patients undergoing fenestrated and branched endovascular thoraco-abdominal and abdominal aortic repair.

| Variable          | All Patients (n = 137) | Degenerative Aneurysms (n = 107) | Post-Dissection Aneurysms (n = 30) | p-Value |
|-------------------|------------------------|----------------------------------|----------------------------------|---------|
| Surgical setting  |                        |                                  |                                  | 0.048   |
| Elective          | 117 (85.4)             | 88 (82.2)                        | 29 (96.7)                        |         |
| Urgent/Emergency | 20 (14.6)              | 19 (17.8)                        | 1 (3.3)                          |         |
| Type of endograft |                        |                                  |                                  | 0.052   |
| Custom-made       | 111 (81.0)             | 83 (77.6)                        | 28 (93.3)                        |         |
| Off-the-shelf     | 16 (11.7)              | 14 (13.1)                        | 2 (6.7)                          |         |
| Surgeon-modified  | 10 (7.3)               | 10 (9.3)                         | 0 (0.0)                          |         |
| Inverted limb     | 17 (12.4)              | 16 (15.0)                        | 1 (3.3)                          | 0.088   |
| Preloaded catheter| 13 (9.5)               | 11 (10.3)                        | 2 (6.7)                          | 0.55    |
| Percutaneous femoral access | 123 (90.8) | 96 (89.7) | 27 (90.0) | 0.99 |
| \( N^* \) of Target vessels | 3.6 ± 0.8 | 3.6 ± 0.8 | 3.9 ± 0.3 | 0.095 |
| CT                | 106 (77)               | 77 (72)                          | 29 (96.7)                        | 0.004   |
| SMA               | 125 (91)               | 95 (88.8)                        | 30 (100)                         | 0.068   |
| RRA               | 130 (94.9)             | 103 (96)                         | 27 (90)                          | 0.177   |
| LRA               | 134 (97.8)             | 107 (100)                        | 30 (100)                         | 0.999   |
| ARA               | 7 (5)                  | 7 (6)                            | 0 (0)                            | 0.347   |
| \( N^* \) of Target vessels ≥4 | 100 (73.0) | 74 (69.0) | 26 (86.7) | 0.056 |
| Type of incorporation |                |                                  |                                  |         |
| n                 | 505                    | 388                              | 117                              |         |
| Scallop           | 22(4.4)                | 22(5.7)                          | 0(0)                             | 0.008   |
| Fenestrations     | 333 (65.9)             | 241 (62)                         | 92 (78.6)                        | 0.001   |
| Branches          | 150 (29.7)             | 125 (32)                         | 25 (21.4)                        | 0.024   |
| Bridging stent diameter, mm |          |                                  |                                  |         |
| CT                | 8 ± 2                  | 8 ± 2                            | 9 ± 1                            | 0.008   |
| SMA               | 8 ± 1                  | 8 ± 1                            | 8 ± 1                            | 0.17    |
| RRA               | 6 ± 1                  | 6 ± 1                            | 7 ± 1                            | 0.040   |
| LRA               | 7 ± 1                  | 6 ± 1                            | 7 ± 1                            | 0.011   |
| Bridging stent sealing length, mm ± SD |          |                                  |                                  |         |
| CT                | 43 ± 26                | 45 ± 28                          | 38 ± 18                          | 0.26    |
| SMA               | 46 ± 24                | 47 ± 23                          | 45 ± 26                          | 0.74    |
| RRA               | 40 ± 24                | 40 ± 25                          | 40 ± 23                          | 0.97    |
| LRA               | 40 ± 23                | 39 ± 23                          | 42 ± 24                          | 0.54    |
| Adjunctive procedures | 41 (29.9) | 24 (22.4) | 17 (56.7) | <0.001 |
| Bifurcation relining | 14 (10.2) | 7 (6.5) | 7 (23.3) | 0.014 |
| Iliac side branch | 31 (22.6)              | 18 (16.8)                        | 13 (43.3)                        | 0.002   |
| Fusion            | 51 (37.3)              | 41 (38.3)                        | 10 (33.3)                        | 0.62    |
| CSF drainage      | 69 (50.4)              | 45 (42.1)                        | 24 (80.0)                        | <0.001  |
| Contrast volume, mL | 300 (200–400) | 300 (200–400) | 400 (300–500) | 0.009 |
| Fluoroscopy time, min | 83 (61–115) | 81 (60–116) | 89 (71–115) | 0.74 |
| Radiation dose, mGy | 3255 (2035–5889) | 3134 (2035–5909) | 4624 (1849–5736) | 0.75 |
| Total procedural time, min | 261 (203–333) | 255 (196–334) | 272 (232–315) | 0.73 |
| Technical success | 133 (97.1)             | 105 (98.1)                       | 28 (97.1)                        | 0.21    |
| Endoleak at final angio | 22 (16.0) | 17 (15.9) | 5 (16.7) | 0.99 |
| Type I            | 4 (2.9)                | 1 (0.9)                          | 3 (10.0)                         | 0.033   |
| Type II           | 16 (11.7)              | 14 (13.1)                        | 2 (6.7)                          | 0.52    |
| Type IIIc         | 2 (1.5)                | 2 (1.9)                          | 0 (0.0)                          | 0.45    |

CT: celiac trunk; LRA: left renal artery; RRA: right renal artery; SMA: superior mesenteric artery. * Categorical variables are presented as n, (%) and continuous variables as mean ± standard deviation or median (inter-quartile range).
3.3. Early Postoperative Outcomes

Technical success was achieved in 97% of the entire cohort (133 patients) without significant difference between groups. The median ICU and total postoperative length of stay (L.O.S) for the entire cohort were 4 (1–4) and 9 (7–16) days respectively, with no significant difference between groups. Furthermore, there was no significant difference between the two groups in terms of major adverse cardiovascular events (MACE) although degenerative aneurysms trended towards higher rates of MACE (14% vs. 3.5%; \( p = 0.19 \)).

Postoperative spinal cord injury was diagnosed in 10 degenerative aneurysms (9.4%) versus 1 post-dissection aneurysm (3.3%; \( p \)-value = 0.45), with paraplegia occurring in a total of 5 patients (3.8%). No type 1a endoleak was recorded at 30 days but type 1b was encountered in a total of seven patients (4.7%) and was significantly higher in post-dissection aneurysms (20% vs. 0.9%). On the other hand, the rate of type II endoleaks was similar in both groups (7.5% versus 6.7%; \( p \): NS). A total of four deaths (2.9%) occurred at 30 days, all four being degenerative aneurysms. The 30-day outcomes are detailed on Table 3.

Table 3. Comparative analysis of 30-day outcomes of FBEVAR in post-dissection and degenerative aneurysms.

| Outcome *          | All (\( n = 137 \))       | Degenerative Aneurysms \( n = 107 \) | Post-Dissection Aneurysms \( n = 30 \) | \( p \)-Value |
|--------------------|---------------------------|--------------------------------------|---------------------------------------|--------------|
| MACE               | 16 (11.8)                 | 15 (14)                              | 1 (3.5)                               | 0.19         |
| Myocardial infarction | 8 (5.8)                  | 8 (7.5)                              | 0 (0.0)                               | 0.20         |
| Acute heart failure | 11 (8.0)                  | 10 (9.9)                             | 1 (3.3)                               | 0.46         |
| Ischemic stroke     | 4 (2.9)                   | 4 (3.7)                              | 0 (0.0)                               | 0.57         |
| Respiratory complications | 10 (7.3)         | 9 (8.4)                              | 1 (3.3)                               | 0.69         |
| Acute kidney injury | 16 (11.7)                 | 12 (11.2)                            | 4 (13.0)                              | 0.75         |
| No dialysis         | 12 (8.8)                  | 10 (9.4)                             | 2 (6.7)                               | -            |
| Temporary dialysis  | 3 (2.2)                   | 1 (0.9)                              | 2 (6.7)                               | -            |
| Permanent dialysis  | 1 (0.7)                   | 1 (0.9)                              | 0 (0.0)                               | -            |
| Spinal cord injury  | 10 (7.5)                  | 9 (8.7)                              | 1 (3.3)                               | 0.45         |
| Paraplegia          | 5 (3.8)                   | 5 (4.9)                              | 0 (0.0)                               | -            |
| Paresis             | 5 (3.8)                   | 4 (3.8)                              | 1 (3.3)                               | -            |
| Ischemic colitis    | 2 (1.5)                   | 2 (1.9)                              | 0 (0.0)                               | 0.99         |
| Access vessel complication | 10 (7.3)           | 8 (7.5)                              | 2 (6.7)                               | 0.999        |
| Femoral access      | 2 (1.5)                   | 2 (1.9)                              | 0 (0.0)                               | 0.999        |
| Surgical wound complication | 4 (2.9)         | 4 (3.7)                              | 0 (0.0)                               | 0.576        |
| Endoleak            |                          |                                      |                                       |              |
| Type I & III        | 21 (15.3)                 | 11 (10.3)                            | 10 (33.0)                             | 0.004        |
| Ia                  | 0 (0.0)                   | 0 (0.0)                              | 0 (0.0)                               | -            |
| Ib                  | 7 (4.7)                   | 1 (0.9)                              | 6 (20.0)                              | <0.001       |
| Ic                  | 1 (0.7)                   | 0 (0.0)                              | 1 (0.8)                               | -            |
| Ila                 | 6 (4.4)                   | 6 (5.6)                              | 0 (0.0)                               | 0.33         |
| Ilc                 | 7 (5.1)                   | 4 (3.7)                              | 3 (10.0)                              | 0.18         |
| Type II             | 10 (7.3)                  | 8 (7.5)                              | 2 (6.7)                               | 0.99         |
| Postoperative LOS, days | 9 (7–16)             | 9 (7–20)                             | 8.5 (7–11)                            | 0.50         |
| ICU length of stay, days | 2 (1–4)                  | 2 (1–4)                              | 3 (2–4)                               | 0.89         |
| Reintervention      | 8 (5.9)                   | 7 (6.5)                              | 1 (3.5)                               | 0.99         |
| Mortality           | 4 (2.9)                   | 4 (3.7)                              | 0 (0.0)                               | 0.58         |

ICU: Intensive care unit; LOS: length of stay; MACE: major adverse cardiovascular event. * Categorical variables are presented as \( n \), (%) and continuous variables as mean ± standard deviation or median (inter-quartile range).
3.4. Short-Term Outcomes

During a mean follow-up of 15 months, no type Ia endoleak was recorded, type Ib was present in 8/133 patients and type Ic in 3 (2.3%). There was no significant difference in the occurrence of type II endoleak between both groups (Table 4); however, the Kaplan–Meier failure estimate of the one-year cumulative rate of types I and III endoleaks was higher in post-dissection aneurysms (35% vs. 13%, \( p = 0.013 \)) as shown on Figure 3. Target-vessel-related interventions (20% vs. 4.9%; \( p = 0.016 \)) and sac progression (36.0% vs. 15.9%, \( p = 0.029 \)) were also more frequent in post-dissection aneurysms. However, no aneurysmal rupture was recorded in any of the groups. The Kaplan–Meier survival estimate of 1-year freedom from graft-related reintervention is illustrated on Figure 4. It was 89 ± 4% for degenerative aneurysms versus 67 ± 10% for post-dissection aneurysms (\( p = 0.011 \)). The factors identified to be associated with unplanned reinterventions in univariate analysis include post-dissection aneurysm, age < 60 years, total procedural time > 240 min and realization of adjunctive procedures (Table 5). A total of nine deaths occurred during follow-up, with an estimated one-year freedom from all-cause mortality of 100% in the post-dissection group versus 91 ± 3% in degenerative aneurysms (Figure 5).

Table 4. Short-term outcomes.

| Outcome * | All \( (n = 133) \) † | Degenerative Aneurysms \( n = 103 \) † | Post-Dissection Aneurysms \( n = 30 \) | \( p \)-Value |
|-----------|----------------------|------------------|------------------|------------|
| Follow-up, months, m (sd) | 15.2 (13.1) | 15.2 (13.3) | 15.3 (12.5) | 0.82 |
| Late Endoleak, n (%) | 37 (27.8) | 23 (22.3) | 14 (46.7) | 0.009 |
| Type I | 11 (8.8) | 3 (2.8) | 8 (30.0) | <0.001 |
| Ia | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
| Ib | 8 (6.0) | 3 (2.9) | 5 (16.7) | 0.015 |
| Ic | 3 (2.3) | 0 (0.0) | 3 (10.0) | 0.011 |
| Type II | 11 (8.3) | 8 (7.8) | 3 (10.0) | 0.71 |
| Type III | 15 (11.0) | 12 (11.2) | 3 (10.0) | 0.85 |
| Illa | 13 (9.5) | 10 (9.4) | 3 (10.0) | 0.7 |
| Illb | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
| Illc | 2 (1.5) | 2 (1.9) | 0 (0.0) | 0.99 |
| Graft limb occlusion | 7 (5.3) | 4 (3.9) | 3 (10.0) | 0.19 |
| Aneurysm rupture | 0 | 0 | 0 | - |
| Aneurysm sac change, mm/year \( (n = 107) \) | −0.1 (−7.0; 3.0) | −0.95 (−7.0; 2.2) | 1.6 (−2.8; 7.3) | 0.40 |
| Sac shrinkage | 28 (26.2) | 22 (26.8) | 6 (26.2) | 0.78 |
| Sac progression | 22 (20.6) | 13 (15.9) | 9 (36.0) | 0.029 |
| Unchanged diameter | 57 (53.3) | 47 (57.3) | 10 (40.0) | 0.13 |
| Late reintervention | 27 (20.3) | 18 (17.5) | 9 (20.3) | 0.13 |
| Target vessel relining/recanalization | 11 (8.3) | 5 (4.9) | 6 (20.0) | 0.016 |
| CT | 2 (1.5) | 1 (1.0) | 1 (3.3) | 0.40 |
| SMA | 3 (2.3) | 1 (1.0) | 2 (6.7) | 0.13 |
| RRA | 4 (3.0) | 2 (1.9) | 2 (6.7) | 0.21 |
| LRA | 6 (4.5) | 2 (1.9) | 4 (13.3) | 0.023 |
| Death | 9 (6.8) | 9 (8.7) | 0 | 0.094 |

CT: celiac trunk; LRA: left renal artery; RRA: right renal artery; SMA: superior mesenteric artery; * Categorical variables are presented as \( n, (%) \) and continuous variables as mean ± standard deviation or median (inter-quartile range). † Four deaths occurred at 30 days and are excluded from analysis.
Categorical variables are presented as \( n \), (%) and continuous variables as mean ± standard deviation or median (inter-quartile range). † Four deaths occurred at 30 days and are excluded from analysis.

Figure 3. Kaplan–Meier failure plot of occurrence of type I and III endoleaks after fenestrated/branched endovascular aortic repair.

Figure 4. Kaplan–Meier failure plot of occurrence of type I and III endoleaks after fenestrated/branched endovascular aortic repair.
4. Discussion

In this study, we compared the clinical characteristics and outcomes of FBEVAR in post-dissection aneurysms to degenerative aneurysms and found the former to be associated with higher rates of types I and III endoleaks and target vessel instability. Moreover, post-dissection aneurysms had a tendency for higher rates of unplanned reinterventions. Unlike degenerative aneurysms, the safety and effectiveness of FBEVAR in post-dissection aortic aneurysms have not been sufficiently established in the literature. However, recent studies have reported favorable outcomes and shown that FBEVAR is feasible in this very important sub-group of patients [7–9]. Oikonomou and colleagues [9] previously reported a technical success rate of 96% and a perioperative mortality of 5.6% in 71 patients undergoing FBEVAR for post-dissection aneurysms. Similarly, Spear et al. [10] reported a technical success rate of 93% with a 30-day mortality of 4.7%, while Tenorio and colleagues [8] reported similar high technical success rates between post-dissection aneurysms and degenerative aneurysms (100% vs. 98.8%; \(p\)-value = 0.14). With a technical success rate of 97% in post-dissection aneurysms, our cohort compares well with previous studies and, similar to Tenorio [8], did not report any significant difference between the two groups. Despite satisfactory technical success rates, unplanned reinterventions continue to be a major issue in FBEVAR and more importantly, in post-dissection aneurysms [11–14]. Oikonomou reported a cumulative reintervention rate of 20% at 1 year, the majority of which were due to target vessel instability and endoleak [9]. Similarly, Marques de Maniro [7] and
colleagues reported a 25% reintervention rate in their cohort of 55 patients with post-dissection aneurysms, while Yuk et al. documented a reintervention rate of 30% with all of them occurring within less than 6 months of index procedure [15]. Furthermore, in comparing post-dissections to degenerative aneurysms, Tenorio [8] reported higher rates of reinterventions in the former (40% vs. 30%). These consistent high rates of reinterventions reported in the literature are a clear indicator of the anatomical complexity and the consequential technical challenges presented by post-dissection aneurysms [8]. As showcased in our cohort, post-dissection aneurysms are mostly extensive TAAA which may require more proximal sealing zones as well as incorporation of all four reno-visceral arteries to achieve successful aneurysmal exclusion [16]. Moreover, the frequent extension of disease into the iliac arteries could account for the high rate of type Ib endoleak observed despite adequate oversizing of the stent–graft. In addition, the presence of intimal flap and thrombosed false lumen in target vessels make their catheterization and expansion of bridging stent more difficult compared to degenerative aneurysms and may lead to longer operating times as well as the need to resort to adjunctive techniques and additional stent–graft components to achieve satisfactory target vessel incorporation [17]. It is well established that the higher the number of stent–graft components, the greater the potential for failure of attachment sites leading to endoleaks and the need for reinterventions [18]. Other major causes of unplanned reinterventions in FBEVAR are graft-limb occlusions and target vessel instability [11,12,19–21]. This was corroborated by our study, with graft limb occlusions occurring in 5% of the cohort, while target vessel relining and recanalization procedures were performed in 11/27 reinterventions. Certain authors have suggested the use of preloaded catheters to facilitate the cannulation of target vessels in post-dissection aneurysms [8,22] as well as the use of cone beam CT imaging for early detection and assessment of bridging stent compression by false lumen [23,24]. Other bailout techniques for difficult target vessel catheterization described in the literature include the balloon-anchoring technique [25], the loop technique [26], the snare-ride [27] and the use of steerable sheaths for retrograde access to antegrade branches [28]. Furthermore, authors such as Oikonomou suggest that using longer bridging stents to achieve adequate sealing in target vessels may help reduce reintervention rates [9]. Regarding bridging stents, it is noteworthy to mention that there are currently no dedicated stents for FBEVAR, and there are no clear guidelines or standardized practice in the choice of bridging stents, which mostly depends on the surgeon’s preferences. In a recent systematic review, Mezzetto and colleagues [29] reported that 40% of all bridging stents were balloon-expandable, and 28% were self-expandable, with the remaining 36% undefined. This situation may, however, change in the future as studies are currently underway to evaluate the safety and efficacy of various bridging stents in FBEVAR [30–33]. The higher rate of reinterventions occurring in the post-dissection group in our series could also be interpreted in the light of higher mortality rates in degenerative aneurysms. Owing to more frequent cardiac comorbidities in this latter group, it could be that some of them are actually dying before reintervention-worthy complications are detected. One particularity of our cohort is the relatively high number of patients receiving concurrent iliac side-branch device implants (23% overall). This proportion was significantly higher in the post-dissection group (43%) and should be considered when interpreting the results of this series, especially with regards to intra-procedural metrics such as total procedural times, radiation doses and amount of contrast volume used.

Limitations

Limitations of this study include its retrospective nature which is inherently a source of information bias. In addition, contrary to some previous studies [8], our cohort encompassed all extents of aneurysms with unequal distributions between the two groups. This, coupled with other differences in baseline characteristics between the two groups, is a potential confounding factor for reintervention rates. Ideally, the risk of bias could be reduced by propensity matching; however, the relatively small number of post-dissection
aneurysms in our cohort would not allow for a robust propensity study nor meaningful multivariate analysis. For this reason, we limited this study to univariate analysis and were thus unable to establish an independent association between the type of aneurysm treated and reintervention. In this regard, it is remarkable that Tenorio and colleagues [8] compared patients with similar aneurysmal extent and reported a trend towards higher reintervention rates in the post-dissection group, with borderline statistical significance (40% vs. 30%, p-value = 0.06). Furthermore, the proportion of patients presenting any type of endoleak was higher among post-dissection aneurysms in that study (76% vs. 43%, p-value = 0.001). These findings suggest a possible independent association, and future studies at a larger multicentric level are warranted to investigate this association further.

5. Conclusions

The outcomes of FBEVAR in post-dissection aneurysms are comparable with those of degenerative aneurysms in terms of technical success. They are also associated with lower perioperative mortality and excellent freedom from aneurysmal rupture. However, reintervention rates tend to be high in the short-term and are mostly due to endoleaks and target vessel instability. Propensity studies are warranted to further investigate the association between post-dissection aneurysms and unplanned graft-related reinterventions.

Author Contributions: Conceptualization, B.B., J.H., R.G.e.M., J.S., C.F.P., M.P., B.R. and N.T.; methodology, B.B., J.H. and J.S.; software, B.B. and J.H.; validation, B.B., J.H., R.G.e.M., J.S., C.F.P., M.P., B.R. and N.T.; formal analysis, B.B., J.H. and N.T.; investigation, J.H., B.B., R.G.e.M., J.S., C.F.P., M.P., B.R. and N.T.; resources N.T.; data curation, J.H., R.G.e.M. and B.B.; writing—draft, B.B. and J.H.; writing—review and editing, B.B., J.H., R.G.e.M., J.S., C.F.P., M.P., B.R. and N.T.; supervision, N.T.; project administration, N.T. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of LMU Klinikum (protocol code 20-177, approved on 25 June 2020).

Informed Consent Statement: Patient consent was waived by the Ethics Committee due to retrospective nature of study.

Data Availability Statement: The underlying data for this study will be made available upon reasonable request to the senior author, N.T.

Conflicts of Interest: The senior author, N.T., is a consultant for Cook Medical.

References
1. Fattori, R.; Montgomery, D.; Lovato, L.; Kische, S.; Di Eusanio, M.; Ince, H.; Eagle, K.A.; Isselbacher, E.M.; Nienaber, C.A. Survival after endovascular therapy in patients with type B aortic dissection: A report from the International Registry of Acute Aortic Dissection (IRAD). JACC Cardiovasc. Interv. 2013, 6, 876–882. [CrossRef] [PubMed]
2. Upchurch, G.R.; Perry, R.J. Thoracic and Thoracoabdominal Aortic Aneurysm: Etiology, Epidemiology, Natural History, Medical Management, and Decision Making. In Rutherford’s Vascular Surgery and Endovascular Therapy, 9th ed.; Elsevier: Philadelphia, PA, USA, 2019; Volume 1, pp. 3266–3324.
3. Tsilimparis, N.; Perez, S.; Dayama, A.; Ricotta, J.J. Endovascular repair with fenestrated-branched stent grafts improves 30-day outcomes for complex aortic aneurysms compared with open repair. Ann. Vasc. Surg. 2013, 27, 267–273. [CrossRef] [PubMed]
4. Simons, J.P.; Crawford, A.S.; Flanagan, C.P.; Aiello, F.A.; Arous, E.J.; Judelson, D.R.; Messina, L.M.; Robichaud, D.I.; Valliere, S.A.; Schanzer, A. Evolution of fenestrated/branched endovascular aortic aneurysm repair complexity and outcomes at an organized center for the treatment of complex aortic disease. J. Vasc. Surg. 2021, 73, 1148–1155.e2. [CrossRef]
5. Oderich, G.S.; Ribeiro, M.; Hofer, J.; Wigham, J.; Cha, S.; Chini, J.; Macedo, T.A.; Gloviczki, P. Prospective, nonrandomized study to evaluate endovascular repair of pararenal and thoracoabdominal aortic aneurysms using fenestrated-branched endografts based on supraceliac sealing zones. J. Vasc. Surg. 2017, 65, 1249–1259.e10. [CrossRef]
6. Oderich, G.S.; Forbes, T.L.; Chaer, R.; Davies, M.G.; Lindsay, T.F.; Mastracci, T.; Singh, M.J.; Timaran, C.; Woo, E.Y. Reporting standards for endovascular aortic repair of aneurysms involving the renal-mesenteric arteries. J. Vasc. Surg. 2021, 73, 4S–52S. [CrossRef] [PubMed]
29. Mezzetto, L.; Scorsone, L.; Silingardi, R.; Gennai, S.; Piffaretti, G.; Mantovani, A.; Bush, R.L.; Haulon, S.; Veraldi, G.F. Bridging stents in fenestrated and branched endovascular aneurysm repair: A systematic review. *Ann. Vasc. Surg.* **2021**, *73*, 454–462. [CrossRef]

30. Torsello, P.G. Physician-Initiated Trial Investigating the BeGraft Peripheral Plus Stent Graft System as Bridging Stent in BEVAR for Complex Aortic Aneurysms. clinicaltrials.gov, Clinical Trial Registration NCT03982940; August 2021. Available online: https://clinicaltrials.gov/ct2/show/NCT03982940 (accessed on 3 March 2022).

31. Torsello, P.G. Physician-Initiated Trial Investigating the BeGraft Peripheral Stent Graft System as Bridging Stent in FEVAR for Complex Aortic Aneurysms. clinicaltrials.gov, Clinical Trial Registration study/NCT03987035; August 2021. Available online: https://clinicaltrials.gov/ct2/show/study/NCT03987035 (accessed on 3 March 2022).

32. W. L. Gore & Associates. Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used as a Bridging Stent with Branched and Fenestrated Endografts in the Treatment of Aortic Aneurysms Involving the Renal-Mesenteric Arteries. clinicaltrials.gov, Clinical Trial Registration NCT05143138; November 2021. Available online: https://clinicaltrials.gov/ct2/show/NCT05143138 (accessed on 3 March 2022).

33. Motta, F.; Parodi, F.E.; Knowles, M.; Crowner, J.R.; Pascarella, L.; McGinigle, K.L.; Marston, W.A.; Kibbe, M.R.; Ohana, E.; Farber, M.A. Performance of Viabahn balloon-expandable stent compared with self-expandable covered stents for branched endovascular aortic repair. *J. Vasc. Surg.* **2021**, *73*, 410–416.e2. [CrossRef]